Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-02-2024 | Diclofenac | News item

Warning against use of Artri King tablets

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

The Australian Therapeutic Goods Administration (TGA) has published a safety advisory warning against the use of Artri King tablets because TGA testing has found that the tablets contain undeclared diclofenac, dexamethasone and phenolphthalein. Each of these substances taken alone or in combination with other medication can cause serious adverse events. …
Literature
Metadata
Title
Warning against use of Artri King tablets
Publication date
01-02-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53097-8

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Alemtuzumab

Case report

Multiple drugs

Case report

Heparin/warfarin

Case report

Baricitinib

Case report

Nitrofurantoin

Case report

Amiodarone